<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prognosis of Wilms tumor
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prognosis of Wilms tumor
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prognosis of Wilms tumor
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Valeria Smith, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Murali Chintagumpala, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wilms tumor is the most common malignancy affecting the kidney(s) in children [
         <a href="#rid1">
          1
         </a>
         ]. Five-year overall survival (OS) rates have dramatically improved with multimodal therapy and now approach 90 percent.
        </p>
        <p>
         The treatment and outcome of Wilms tumor will be reviewed here. The epidemiology, presentation, diagnosis, and staging of Wilms tumor are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PROGNOSTIC FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several prognostic factors at the time of initial diagnosis are associated with an increased risk of tumor recurrence or death and include [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor histology
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor stage
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular and genetic markers (eg, loss of heterozygosity [LOH] at chromosome 16q, 1p, and 11p15 and 1q gain)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &gt;2 years
        </p>
        <p>
        </p>
        <p>
         These prognostic factors are taken into account when determining the initial treatment regimen. (See
         <a class="local">
          'COG approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Tumor histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumor histology is linked to patient outcome. Histologic classification differs somewhat between the two major Wilms tumor research groups (ie, Children's Oncology Group [COG] and the International Society of Paediatric Oncology [SIOP]). (See
         <a class="local">
          'Difference in approaches of COG and SIOP'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4102813861">
         <span class="h3">
          Histologic classification systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         In COG protocols, histologic assessment is performed before chemotherapy and tumors are categorized according to the presence or absence of anaplasia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Favorable histology (ie, no anaplasia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal anaplasia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse anaplasia
        </p>
        <p>
        </p>
        <p>
         The SIOP system assigns a histologic classification based upon assessment after preoperative chemotherapy  (
         <a class="graphic graphic_table graphicRef106103" href="/z/d/graphic/106103.html" rel="external">
          table 1
         </a>
         ). Tumors are classified as low, intermediate, or high risk based upon the degree of tumor necrosis and the relative proportion of each of the three cell types (epithelial, stromal, or blastemal). Patients with diffuse anaplastic or blastemal-type tumor after chemotherapy are classified as having high-risk histology. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12305109">
         <span class="h3">
          Anaplastic histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of anaplasia is the most important predictor of adverse outcome in children with Wilms tumor [
         <a href="#rid3">
          3,4
         </a>
         ]. Anaplasia is defined as the presence of multipolar polypoid mitotic figures and marked nuclear enlargement with hyperchromasia  (
         <a class="graphic graphic_picture graphicRef106079" href="/z/d/graphic/106079.html" rel="external">
          picture 1
         </a>
         ), and it can be further classified as either focal (defined as tumors with anaplasia confined to one or a few discrete loci within the primary tumor, with no anaplasia or marked nuclear atypia elsewhere) or diffuse [
         <a href="#rid3">
          3
         </a>
         ]. Most anaplastic Wilms tumors have
         <em>
          TP53
         </em>
         gene mutations [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
         In a report from the National Wilms Tumor Study (NWTS) group, multivariate analysis of 632 patients with nonmetastatic disease at diagnosis demonstrated that anaplastic, rhabdoid, or clear cell sarcoma histology was associated with increased rates of recurrence, metastases, and death [
         <a href="#rid6">
          6
         </a>
         ]. Although diffuse anaplasia was only seen in 10 percent of patients, those with diffuse anaplastic tumor accounted for more than 60 percent of the deaths [
         <a href="#rid7">
          7
         </a>
         ]. In the 165 cases with anaplastic histology, only three relapses and one death occurred among the 39 cases with focal anaplasia. In contrast, 22 of 23 children with stage IV diffuse anaplasia died of causes related to the tumor.
        </p>
        <p>
         In another report from the NWTS group, diffuse anaplasia was the most significant predictor of a shorter survival time after diagnosis [
         <a href="#rid8">
          8
         </a>
         ]. A subsequent study summarizing the results of the fifth NWTS demonstrated that the presence of focal or diffuse anaplasia in patients with stage I and stage II disease is associated with an inferior four-year overall survival (OS) rate when compared with patients with favorable histology tumors (approximately 83 versus 98 percent) [
         <a href="#rid9">
          9
         </a>
         ]. For patients with diffuse anaplasia who underwent an immediate nephrectomy at diagnosis, patients with stage III or IV disease also fared worse at four years compared with those with favorable histology who were treated on the fifth NWTS (stage III anaplasia 65 percent, stage IV anaplasia 33 percent, and stage III or IV with favorable histology 92 percent).
        </p>
        <p class="headingAnchor" id="H12305115">
         <span class="h3">
          Blastemal type histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blastemal type histology, assessed after preoperative chemotherapy (as in SIOP protocols), also appears to be associated with poor outcome; however, blastemal content has no prognostic significance when histologic categorization is performed before chemotherapy (as in COG protocols).
        </p>
        <p>
         Results from retrospective analyses of earlier SIOP trials suggest that patients with blastemal type Wilms tumor have five-year event-free survival (EFS) of approximately 60 to 70 percent [
         <a href="#rid10">
          10,11
         </a>
         ]. In particular, the risk of relapse appears to be higher among patients with blastemal type histology compared with other histologic subtypes of nonanaplastic Wilms tumor [
         <a href="#rid12">
          12
         </a>
         ]. Based on these findings, SIOP reclassified this subtype as "high-risk" histology in 2002 [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Tumor stage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staging criteria for Wilms tumor are based on the anatomic extent of the tumor without consideration for genetic, histologic, or molecular markers [
         <a href="#rid14">
          14
         </a>
         ]. Higher stages (stages III through V) are associated with more extensive disease and a poorer outcome when compared with patients with lower stage disease (I and II) [
         <a href="#rid6">
          6,15-18
         </a>
         ]. (See
         <a class="local">
          'Outcome'
         </a>
         below.)
        </p>
        <p>
         There are two major staging systems in use  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         COG staging – The COG surgical staging occurs
         <strong>
          prior
         </strong>
         to administration of chemotherapy and is used throughout the United States and Canada
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SIOP staging – The SIOP surgical staging occurs
         <strong>
          after
         </strong>
         four weeks of chemotherapy and is used extensively in Europe
        </p>
        <p>
        </p>
        <p>
         Both staging criteria are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Staging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Molecular markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several molecular and genetic markers appear to be predictive of outcome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LOH and 1q gain
         </strong>
         – LOH at chromosomes 1p, 11p15, and 16q and 1q gain in tumor cells are associated with risk of relapse and mortality in some patients with favorable histology Wilms tumor [
         <a href="#rid19">
          19-28
         </a>
         ]. These findings have prompted the incorporation of some of these markers into the assignment of risk-directed therapy in children with Wilms tumor [
         <a href="#rid21">
          21,26,27,29,30
         </a>
         ]. (See
         <a class="local">
          'COG approach'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gene expression profiles
         </strong>
         – Gene expression profiles also have been shown to be predictive of outcome and may ultimately aid in patient stratification and assignment to different treatment regimens, especially identifying patients who may require surgery only [
         <a href="#rid31">
          31-34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H861562494">
         <span class="h2">
          Age
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, children &lt;24 months of age generally had lower relapse rates than older patients, which resulted in a better clinical outcome [
         <a href="#rid35">
          35
         </a>
         ]. With improved therapeutic interventions, the effect of age as a prognostic factor has been reduced [
         <a href="#rid6">
          6,36
         </a>
         ].
        </p>
        <p>
         Adults with Wilms tumor have the same survival rate as children with similar tumor histology and stage when treated with the same therapeutic regimens [
         <a href="#rid37">
          37,38
         </a>
         ]. However, the rate of treatment-related toxicity appears to be higher in adult patients [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with suspected Wilms tumor should be referred to a pediatric cancer center for evaluation and treatment. Most children with newly diagnosed Wilms tumor are treated on research protocols, and risk-based therapy is assigned based on results of the initial staging, histologic classification, and molecular studies. These regimens conducted by cooperative groups incorporate multimodal therapy (surgery, chemotherapy, and radiation) and have resulted in dramatic improvements in outcomes in these children, with overall five-year survival rates approaching 90 percent. (See
         <a class="local">
          'Outcome'
         </a>
         below and
         <a class="local">
          'Prognostic factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H734648">
         <span class="h2">
          Difference in approaches of COG and SIOP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two major research groups that care for the largest number of patients with Wilms tumor are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children's Oncology Group (COG)
         </strong>
         – The National Wilms Tumor Study (NWTS) group was established in 1969 and was subsequently incorporated into the COG, which conducts all trials in children with Wilms tumor in North America. The authors of this topic review practice at a COG member institution.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International Society of Paediatric Oncology (SIOP)
         </strong>
         – The SIOP group was established in the early 1970s. It primarily includes European pediatric oncology centers, with additional centers located in South America and Australia.
        </p>
        <p>
        </p>
        <p>
         COG and SIOP differ in their management of unilateral Wilms tumor (stages I through IV Wilms tumor), specifically regarding the timing of chemotherapy relative to surgical excision [
         <a href="#rid22">
          22
         </a>
         ]. COG encourages the use of primary surgical resection
         <strong>
          prior
         </strong>
         to chemotherapy administration. In contrast, SIOP protocols use a primary chemotherapy approach followed by surgical resection and staging four weeks
         <strong>
          after
         </strong>
         the administration of chemotherapy. Both treatment approaches have excellent and comparable clinical outcomes [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Outcome'
         </a>
         below.)
        </p>
        <p>
         The COG approach has the following advantages:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It allows early accurate assessment of the histologic diagnosis and tumor extent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It prevents patients with benign tumors from receiving unnecessary chemotherapy. SIOP trials have reported approximately 1.5 percent of patients treated initially with chemotherapy were found to have benign tumors [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The SIOP approach has the following advantages:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preoperative chemotherapy usually reduces tumor volume and may make surgical excision easier, thus decreasing the likelihood of tumor spillage [
         <a href="#rid41">
          41
         </a>
         ]. This appears to reduce the potential need for local radiation due to spillage of tumor cells [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The SIOP approach incorporates a measure of the in vivo chemosensitivity of each child's tumor into risk stratification, which has allowed reduction of treatment intensity for children with localized stage II or III Wilms tumor [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study from the United Kingdom Children's Cancer Study (UKCCS) Group, 205 patients with newly diagnosed, potentially resectable kidney tumors were randomized to immediate nephrectomy, or percutaneous kidney biopsy followed by chemotherapy and then nephrectomy [
         <a href="#rid44">
          44
         </a>
         ]. There was improvement in the stage distribution among patients treated with preoperative chemotherapy and delayed surgery compared with those having immediate nephrectomy, which resulted in 20 percent fewer children receiving radiotherapy or
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         . However, there was no difference between the two groups in five-year event-free survival (EFS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent report from the UKCCS group, delayed nephrectomy preceded by preoperative chemotherapy was associated with fewer surgical complications (including tumor rupture and spillage) compared with treatment with immediate nephrectomy (1 versus 20 percent) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nonetheless, the COG and SIOP regimens have comparable five-year overall and EFS rates. (See
         <a class="local">
          'Survival rate'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          COG approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         COG protocols are based upon primary surgical resection as initial treatment for children with unilateral Wilms tumor  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4,6,16,46-50
         </a>
         ]. Adjuvant chemotherapy is administered after surgery. The choice of chemotherapeutic agents and the length of therapy are dependent upon the tumor histology and stage  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ). Radiation therapy is used in patients with stage III or IV tumors. (See
         <a class="local">
          'Tumor histology'
         </a>
         above and
         <a class="local">
          'Tumor stage'
         </a>
         above.)
        </p>
        <p>
         Because the authors' institution is a member of COG, they treat patients using COG protocols or use these protocols as guidelines for therapy  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. The approach is based upon the tumor stage as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stages I and II
         </strong>
         – Primary surgical resection is followed by 19 weeks of
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         . No radiation therapy is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The treatment approach may be modified in patients with any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Very low-risk tumors
         </strong>
         – Patients meeting
         <strong>
          all
         </strong>
         of the following criteria are considered to have very low-risk tumors:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age &lt;2 years
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Stage I favorable histology
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tumor weighs &lt;550 g
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Most patients with very low-risk tumors can be managed by nephrectomy alone without adjuvant chemotherapy [
         <a href="#rid51">
          51-53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In one study, patients with very low-risk tumors were assigned to either surgery alone or surgery followed by adjunctive chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) [
         <a href="#rid52">
          52,54
         </a>
         ]. According to the study's stringent stopping rule, the study was closed when the predicted two-year EFS fell below 90 percent. At two years, the rate of relapse among patients treated with surgery alone was 13.5 percent; all patients were alive [
         <a href="#rid54">
          54
         </a>
         ]. In a report of long-term outcomes of the patients in this study, five-year EFS was lower for patients treated with surgery only compared with surgery plus adjuvant chemotherapy (84 versus 97 percent) [
         <a href="#rid52">
          52
         </a>
         ]. One death was observed in each treatment group, and five-year overall survival (OS) did not differ between groups (98 and 99 percent). Investigators observed that the children who relapsed were more successfully retreated compared with similar patients in previous studies, probably because they were naive to both radiation therapy and chemotherapy. The authors concluded that although EFS was lower in the surgery only group, the overall mortality rate did not differ and a majority of the infants in the surgery only group were spared the adverse effects of chemotherapy. This study is limited in that 21 of the 77 patients initially treated with surgery alone were later recalled and treated with chemotherapy and were therefore censored from the analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a subsequent trial, 116 children with very low-risk tumors (excluding patients with predisposition syndromes and those with inadequate lymph node sampling) were treated with nephrectomy alone followed by close observation over a median follow-up of 80 months [
         <a href="#rid53">
          53
         </a>
         ]. Estimated four-year EFS was 90 percent, and no deaths occurred. Loss of heterozygosity (LOH) at chromosome 11p15 was predictive of relapse. (See
         <a class="local">
          'Molecular markers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High-risk molecular markers
         </strong>
         – As discussed above, certain molecular markers (eg, LOH at chromosomes 1p, 11p15, and 16q and 1q gain) are associated with lower OS and EFS in patients with otherwise favorable histology (see
         <a class="local">
          'Molecular markers'
         </a>
         above). Preliminary data suggest that augmentation of therapy for patients with some of these high-risk markers may improve outcomes. For example, in a single-arm study involving 35 patients with standard-risk stage I and II tumors with combined LOH at chromosomes 1p and 16q, the addition of
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         to the chemotherapy regimen was associated with a nonsignificant trend towards improved four-year EFS compared with similar patients enrolled in an earlier study who were treated without doxorubicin (84 percent versus 75 percent, respectively) [
         <a href="#rid29">
          29
         </a>
         ]. It is uncertain whether augmented therapy will improve outcomes for patient with tumors displaying 1q gain. Further studies are needed to address this question.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anaplasia
         </strong>
         – Patients with stage I/II disease and anaplastic histology have a poorer prognosis and are treated with additional chemotherapy and radiation therapy as described below. (See
         <a class="local">
          'Anaplastic histology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage III
         </strong>
         – Primary surgical resection is followed by 25 weeks of three-drug chemotherapy with
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         . Radiation therapy (dose of 10.8 radiation absorbed dose [Gy]) based on lymph node involvement or the extent of the peritoneal contamination is administered to the affected flank, hemiabdomen, or complete abdomen. Most patients with stage III favorable histology have good outcomes with this treatment approach (ie, four-year EFS of 88 percent) [
         <a href="#rid55">
          55
         </a>
         ]. Positive lymph nodes and LOH at either chromosome 1p or 16q are predictors of poor outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with combined LOH at chromosomes 1p and 16q are treated with a more intensive chemotherapy regimen (ie, "regimen M," which includes
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ). In a single-arm COG study involving 52 patients with stage III/IV favorable histology tumor with 1p and 16q LOH who were treated with regimen M, four-year EFS was superior to that of a similar cohort enrolled in an earlier study and received less intensive therapy (90 percent versus 61 percent, respectively) [
         <a href="#rid29">
          29,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage IV
         </strong>
         – Primary surgical resection is followed by 25 weeks of triple-drug chemotherapy of
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         . As with stage III, patients with combined LOH at chromosomes 1p and 16q are treated with a more intensive chemotherapy (regimen M) [
         <a href="#rid57">
          57
         </a>
         ]. Radiation therapy is administered to the whole lung field only if lung metastases do not completely resolve after six weeks of chemotherapy [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="local">
          'Lung metastases'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with evidence of spread of disease to the regional lymph nodes in the hilum and/or paraaortic nodes, radiation therapy (dose of 10.8 radiation absorbed dose [Gy]) is administered to the locoregional area including the appropriate one-half of the abdomen as indicated. For patients with metastatic sites other than the lung, radiation dose varies according to the site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage V
         </strong>
         – Treatment of bilateral (stage V) Wilms tumor is reviewed below. (See
         <a class="local">
          'Bilateral kidney involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          SIOP approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         In SIOP protocols  (
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         ), patients are treated with preoperative chemotherapy for four weeks (six weeks if there is evidence of metastatic disease) followed by surgical resection and postoperative chemotherapy that is based upon the staging and histology assessment performed after initial chemotherapy  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid13">
          13,14,39,40,43,58-60
         </a>
         ].
        </p>
        <p>
         For patients with nonmetastatic disease, preoperative chemotherapy consists of
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         for four weeks. If there is evidence of metastatic disease beyond the abdominal-peritoneal region (eg, lung metastases), triple-drug chemotherapy (vincristine, dactinomycin, and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ) is given for six weeks preoperatively. Following preoperative chemotherapy, surgical resection and staging are performed.
        </p>
        <p>
         In some centers, biopsies are used to make a histologic diagnosis prior to the initiation of chemotherapy [
         <a href="#rid61">
          61
         </a>
         ]. In the SIOP Wilms tumor 2001 study, biopsy was allowed without affecting tumor stage [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Staging'
         </a>
         .)
        </p>
        <p>
         Postoperative SIOP regimens are based upon tumor staging and histology as follows  (
         <a class="graphic graphic_table graphicRef106103" href="/z/d/graphic/106103.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage I:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low risk
         </strong>
         – Patients with low-risk stage I tumors (ie, no viable tumor after initial preoperative chemotherapy) do not require additional chemotherapy or radiation therapy. These patients are monitored closely for recurrence. (See
         <a class="local">
          'Screening for tumor recurrence'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intermediate risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) for four weeks without radiation therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ) for 27 weeks without radiation therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage II:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low and intermediate risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) for 27 weeks without radiation therapy. Although previously included in SIOP treatment protocols, the elimination of
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         from the postoperative regimen did not significantly worsen EFS and had no effect on five-year OS in patients with intermediate-risk histology [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ) for 34 weeks and radiation therapy (25.2 Gy flank radiotherapy with a 10.8-Gy boost for lymph node involvement or gross disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage III:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) for 27 weeks without radiation therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intermediate risk
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) for 27 weeks and radiation therapy (14.4 Gy flank radiotherapy with a 10.8 Gy boost for lymph node involvement or gross disease). As with stage II tumors, the elimination of
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         from the postoperative regimen did not significantly worsen outcomes in patients with intermediate-risk histology [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – As with stage II high-risk tumors, treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ) for 34 weeks and radiation therapy (25.2 Gy flank radiotherapy with a 10.8-Gy boost for lymph node involvement or gross disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage IV
         </strong>
         – Treatment is based on histology and response of lung nodule(s) after the initial six weeks of preoperative chemotherapy (see
         <a class="local">
          'Lung metastases'
         </a>
         below):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low- and intermediate-risk histology with complete response (ie, resolution or resection of lung nodules)
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ) for 27 weeks without lung irradiation. Flank radiotherapy is provided for patients with local stage III tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low- and intermediate-risk histology with incomplete response
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ) for 34 weeks and radiation therapy (15 Gy lung radiotherapy and flank radiotherapy for local stage III tumors).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High-risk histology
         </strong>
         – Treatment consists of postoperative chemotherapy (
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ) for 34 weeks and radiation therapy (15 Gy lung radiotherapy and flank radiotherapy for local stage III tumors).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with metastatic sites other than the lung, radiation dose varies according to the site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage V
         </strong>
         – Treatment of bilateral (stage V) Wilms tumor is reviewed below. (See
         <a class="local">
          'Bilateral kidney involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H66006083">
         <span class="h2">
          Special populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bilateral (stage V) Wilms tumor, anaplastic histology, and/or lung metastases generally require more intensive therapy than those with lower-grade tumors with standard-risk histology.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Bilateral kidney involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with bilateral Wilms tumor (stage V)  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ), we suggest preoperative chemotherapy with
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         rather than other regimens. Following postoperative therapy, we suggest kidney parenchymal-sparing resection rather than more extensive bilateral kidney resection. Postoperative chemotherapy with or without radiation is selected based on treatment response to neoadjuvant chemotherapy, histopathology, and tumor stage. Preoperative combination chemotherapy reduces the risk of end-stage kidney failure by facilitating early nephron-sparing surgery and preserving kidney parenchyma. The treatment approach for children with stage V Wilms tumor is similar in COG and SIOP protocols [
         <a href="#rid2">
          2,62-64
         </a>
         ].
        </p>
        <p>
         In the COG protocol, which the authors use at their institution, preoperative chemotherapy consists of a six-week regimen of
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         [
         <a href="#rid63">
          63,64
         </a>
         ]. Postoperative chemotherapy with or without radiation is offered based on a risk-adapted protocol that integrates clinical and histologic responses to preoperative chemotherapy, pathologic classification, and tumor stage [
         <a href="#rid63">
          63,64
         </a>
         ]. Specific treatment details of postoperative therapy may be individualized by an institution and are beyond the scope of this review. However, all treatment should be administered under the guidance of a multidisciplinary team of pediatric oncologists, surgeons, and radiation oncologists with expertise in the management of Wilms tumor.
        </p>
        <p>
         Although a minority (only 5 to 7 percent) of patients with Wilms tumors present with stage V disease (bilateral kidney involvement), their care is challenging. In these patients, the therapeutic goal is to adequately treat the bilateral tumor loci while trying to preserve kidney function. Historically, the management of patients with bilateral disease included initial nephrectomy of the more involved side combined with partial nephrectomy or excisional resection of the lesion in the contralateral kidney (initial surgical excision). However, the risk of end-stage kidney disease (ESKD) was high in patients treated with this approach [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="local">
          'Late effects'
         </a>
         below.)
        </p>
        <p>
         Subsequent studies demonstrated improved outcomes with the use of intensive chemotherapy followed by a strategy of kidney parenchymal-sparing resection. In a prospective study conducted by the COG (AREN0534), 189 evaluable patients with bilateral Wilms tumor were treated with 6 to 12 weeks of preoperative chemotherapy followed by tumor resection [
         <a href="#rid63">
          63,64
         </a>
         ]. In this study, a majority of patients (84 percent) underwent definitive surgical treatment by 12 weeks after initiation of chemotherapy [
         <a href="#rid63">
          63
         </a>
         ]. Most patients received unilateral total nephrectomy with contralateral partial nephrectomy (48 percent) or bilateral partial nephrectomy (35 percent). In contrast, bilateral total nephrectomies were performed on less than 3 percent of patients. Four-year EFS and OS were 82 and 95 percent, respectively, which were considerably higher than historical controls (eight-year EFS between 40 and 74 percent; eight-year OS between 45 and 89 percent) [
         <a href="#rid62">
          62
         </a>
         ]. Retrospective studies have reported similar results for neoadjuvant chemotherapy, with reduced rates of kidney failure and overall patient survival rates that are comparable with those receiving initial surgical excision [
         <a href="#rid62">
          62,66,67
         </a>
         ].
        </p>
        <p>
         Patients with diffuse anaplasia (a high-risk tumor) have a poor prognosis despite the use of preoperative chemotherapy. In a subsequent analysis of COG AREN0534, 180 evaluable patients were risk classified  (
         <a class="graphic graphic_table graphicRef106103" href="/z/d/graphic/106103.html" rel="external">
          table 1
         </a>
         ) based on their histopathologic response to preoperative chemotherapy. In this study, four-year EFS and OS was highest for those with low-risk disease and completely necrotic tumors (100 percent each), those with intermediate-risk disease (82 and 97 percent), and those with high-risk blastemal type tumors (79 and 93 percent), respectively. Patients with diffuse anaplasia had the lowest survival rates (four-year EFS and OS of 61 and 72 percent, respectively). [
         <a href="#rid64">
          64
         </a>
         ]. Similar results were seen in another study of 80 children with bilateral tumors where intensive preoperative chemotherapy was not associated with improved OS in patients with diffuse anaplasia or blastemal-type tumors [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="local">
          'Anaplastic histology'
         </a>
         below and
         <a class="local">
          'Blastemal type histology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Anaplastic histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with anaplastic histology have a poorer outcome [
         <a href="#rid9">
          9
         </a>
         ]. As a result, trials investigating alternative agents (eg,
         <a class="drug drug_pediatric" data-topicid="13238" href="/z/d/drug information/13238.html" rel="external">
          irinotecan
         </a>
         ) and using more intensive therapy have been conducted in patients with anaplastic Wilms tumor [
         <a href="#rid69">
          69,70
         </a>
         ]. Despite the more aggressive intervention, the four-year EFS is poor (33 to 70 percent, depending on tumor stage) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Ongoing clinical trials are underway, and future trials are planned in the hope of finding a more effective regimen that will improve EFS in patients with diffuse anaplastic Wilms tumor. An ongoing COG study (AREN1921), is investigating "regimen UH-3" for stages II to IV diffuse anaplastic Wilms tumors [
         <a href="#rid71">
          71
         </a>
         ]. The UH-3 regimen consists of and alternates cycles of
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         , cyclophosphamide/carboplatin/
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         , and vincristine/irinotecan, lasting for a total of 40 weeks.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Lung metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest imaging for patients with Wilms tumor is an area of controversy. A contrast-enhanced computed tomography (CT) is more sensitive than chest radiography; however, it is unclear how many nodules detected by CT represent malignant disease and whether diagnosing these lesions improves outcome. This issue is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p>
         In patients with lung metastases, the optimal management remains uncertain. The approaches of both COG and SIOP attempt to tailor treatment based upon the completeness of lung metastasis response after initial chemotherapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the COG study, patients with favorable histology and isolated lung metastases who showed complete resolution of lung metastases after six weeks of chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ) were continued on the same chemotherapy regimen without lung irradiation [
         <a href="#rid57">
          57
         </a>
         ]. Patients with either an incomplete response after six weeks of chemotherapy or LOH at chromosomes 1p and 16q received whole-lung radiation and the addition of
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         (regimen M). Of the 292 patients enrolled in the study who had lung metastases reassessed after six weeks of therapy, 46 percent had a complete response to initial chemotherapy and 54 percent had an incomplete response. For patients with a complete response, four-year EFS and OS estimates were 79.5 percent (95% CI, 71.2-87.8 percent) and 96.1 percent (95% CI, 92.1-100.0 percent), respectively. For patients with an incomplete response, four-year EFS and OS estimates were 88.5 percent (95% CI, 81.8-95.3 percent) and 95.4 percent (95% CI, 90.9-99.8 percent), respectively. The pooled four-year EFS and OS estimates for the entire cohort were significantly higher compared with an earlier study in which all patients were treated with lung irradiation (85 versus 73 percent and 96 versus 84 percent, respectively). These results suggest that the strategy of tailoring treatment to the patient's response to initial chemotherapy can maintain excellent outcomes for children with lung metastases while decreasing treatment-related morbidity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SIOP 93-01 trial, patients with an incomplete response after six weeks of prenephrectomy chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         /
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         ) underwent surgical resection of the lung nodule if feasible [
         <a href="#rid72">
          72
         </a>
         ]. Patients showing complete resolution of lung metastases after six weeks of prenephrectomy chemotherapy and those who underwent successful surgical resection of lung nodules were then treated with postoperative chemotherapy (vincristine, dactinomycin, and doxorubicin/epirubicin for 27 weeks) without lung irradiation. Patients with incompletely resected lung nodules, multiple inoperable metastases, and/or high-risk histology of the primary tumor were treated with a more intense post-nephrectomy chemotherapy regimen (doxorubicin/epirubicin,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         for 34 weeks). If a complete response was obtained after nine weeks, lung irradiation was not given. In children with residual lung nodules and/or high-risk histology, bilateral pulmonary lung radiotherapy was administered. Only 14 percent of patients in the trial required lung irradiation during first-line treatment. Five-year EFS was 73 percent, and OS was 82 percent. Five-year OS was superior among patients with a complete response after six weeks of prenephrectomy chemotherapy and for those who underwent metastasectomy when compared with those who had an incomplete response (88, 92, and 48 percent, respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1781533389">
         <span class="h2">
          Salvage therapy for tumor recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent disease occurs in approximately 15 percent of patients with favorable histology; however, among patients with anaplastic features, the risk of recurrence is considerably higher. (See
         <a class="local">
          'Tumor recurrence'
         </a>
         below.)
        </p>
        <p>
         The optimal salvage therapy regimen for patients with Wilms tumor has not yet been established. Multiagent regimens with
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13373" href="/z/d/drug information/13373.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13162" href="/z/d/drug information/13162.html" rel="external">
          cisplatin
         </a>
         have been used to varying degrees of success [
         <a href="#rid73">
          73-85
         </a>
         ].
        </p>
        <p>
         High-dose chemotherapy with stem cell rescue has been suggested as an option in patients with recurrent tumor, especially in those with adverse prognostic indicators. However, the efficacy of this approach remains unknown [
         <a href="#rid14">
          14,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          OUTCOME
         </span>
        </p>
        <p class="headingAnchor" id="H110256064">
         <span class="h2">
          Survival rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall five-year survival rates for Wilms tumor have steadily improved from 20 percent in the late 1960s to &gt;90 percent in current-era reports from the Children's Oncology Group (COG), International Society of Paediatric Oncology (SIOP), and other groups [
         <a href="#rid14">
          14,40,48,87
         </a>
         ].
        </p>
        <p>
         In a review of 6185 patients enrolled in the National Wilms Tumor Study (NWTS) between 1969 and 1995, the overall survival (OS) rate was 84 percent through 2002 [
         <a href="#rid88">
          88
         </a>
         ]. Causes of death included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor-related – 86 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late effects of therapy – 9 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nontreatment or nondisease-related – 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unknown – 1 percent
        </p>
        <p>
        </p>
        <p>
         Ninety-one percent of deaths occurred early within the first five years of diagnosis (n = 819) and were primarily due to the original tumor (94 percent). In contrast, the causes of the 159 late deaths were evenly distributed between the late effects of therapy (39 percent) and tumor-related mortality (40 percent).
        </p>
        <p>
         OS and event-free survival (EFS) rates vary among individuals and are dependent upon the tumor histology, stage, and size and age of the patient at diagnosis. Patients with very low-risk tumors (ie, patients &lt;24 months old with stage I favorable histology tumors &lt;550 g) have the best prognosis, with five-year OS rates ≥98 percent [
         <a href="#rid52">
          52
         </a>
         ]. Patients with diffuse anaplastic tumor have the poorest prognosis, with four-year EFS estimates of 83, 65, and 33 percent for stages II, III, and IV, respectively [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         A summary of the outcomes of patients enrolled in COG studies is available through the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fkidney%2Fhp%2Fwilms-treatment-pdq&amp;token=ZzNQP0M0NCTb0JcyOvhxglIbUQ6Vo0n0XhdhSRFdCM75Nmuruk3nN48L4UXZlAv%2FPCNOzOiK4CwYIenZVtkgnQ%3D%3D&amp;TOPIC_ID=6237" target="_blank">
          National Cancer Institute website
         </a>
         .
        </p>
        <p>
         Survivors of childhood Wilms tumor are at increased risk of premature death during adulthood due to secondary neoplasms and other late complications (see
         <a class="local">
          'Late effects'
         </a>
         below). In the British Childhood Cancer Survivor Study, which included 1441 five-year survivors of Wilms tumor, the cumulative risk of death at 30 and 50 years from diagnosis was 5 and 23 percent, respectively [
         <a href="#rid89">
          89
         </a>
         ]. Three-quarters of excess late deaths in this cohort were attributable to secondary neoplasms; cardiovascular disease accounted for the remainder.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Tumor recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent disease occurs in approximately 15 percent of patients with favorable histology; however, among patients with anaplastic features, the risk of recurrence is nearly 50 percent [
         <a href="#rid9">
          9
         </a>
         ]. Unfavorable histology is the most powerful prognostic factor associated with tumor recurrence [
         <a href="#rid50">
          50,90,91
         </a>
         ]. Other risk factors include tumor size, tumor stage, age, and presence of certain molecular markers. (See
         <a class="local">
          'Prognostic factors'
         </a>
         above.)
        </p>
        <p>
         For patients with stage III disease, the risk of recurrence does not appear to differ according to stage III subtype [
         <a href="#rid92">
          92
         </a>
         ]. Biopsy is thought to increase the risk of local recurrence by introducing tumor cells into the abdominal cavity. However, a study investigating this found that biopsy is not clearly associated with increased risk of local recurrence [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         The majority of recurrences occur within the first two years of therapy. Recurrences most often involve the lung. Recurrence in the central nervous system is very rare [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         Approximately 1 percent of children develop a tumor in the contralateral kidney within six years of the initial diagnosis of Wilms tumor, with 90 percent occurring within the first two years [
         <a href="#rid16">
          16,48
         </a>
         ]. The presence of nephrogenic rests (foci of persistent metanephric cells) places a child at increased risk for contralateral kidney recurrence [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         Patients who have recurrence of their tumor have post-relapse four-year survival rates of 50 to 80 percent [
         <a href="#rid95">
          95,96
         </a>
         ]. In a study of children who relapsed after receiving two chemotherapeutic agents (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and actinomycin D), salvage therapy (which included
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         , and radiation therapy) was associated with 82 percent OS and 71 percent EFS rates at four years [
         <a href="#rid95">
          95
         </a>
         ]. In a study of children who relapsed after receiving initial therapy with vincristine, actinomycin D, doxorubicin, and radiation therapy, salvage therapy using an aggressive chemotherapy regimen (including cyclophosphamide and
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         along with surgery and radiation therapy) was associated with 48 percent OS and 42 percent EFS rates at four years [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
         In patients with recurrent tumor, the following prognostic factors are associated with favorable response to salvage therapy and improved outcome [
         <a href="#rid14">
          14,97-99
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relapse occurs more than 12 months after initial diagnosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Favorable histology of the initial tumor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low tumor stage of initial disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial treatment with only
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Few pulmonary nodules
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No previous radiation to tumor bed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete resection of original tumor
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Early complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early complications are generally related to therapy and include adverse effects of chemotherapeutic drugs and surgical complications such as bowel obstruction, hemorrhage, and wound infection [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Late effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Survivors are at increased risk for long-term sequelae [
         <a href="#rid101">
          101
         </a>
         ]. Late adverse effects are primarily dependent upon the type and intensity of therapy used to treat patients. Patients who received more intense chemotherapy and radiation therapy are more likely to have late complications. These include kidney impairment; cardiotoxicity; hepatotoxicity; orthopedic, growth, and pulmonary problems; infertility; and secondary malignancies [
         <a href="#rid102">
          102-104
         </a>
         ]. All patients should undergo routine screening for therapy-related complications.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney impairment
         </strong>
         – Kidney impairment may be caused by surgical loss of kidney parenchyma as well as kidney injury from chemotherapy and radiation therapy. Patients with bilateral kidney involvement are at increased risk for kidney impairment, especially if they also received radiation therapy [
         <a href="#rid18">
          18,65,105-107
         </a>
         ]. This was illustrated from a study from the National Wilms Tumor Study (NWTS) group of 81 patients with stage V tumor who received radiation therapy [
         <a href="#rid106">
          106
         </a>
         ]. One-third of patients had elevated serum creatinine concentrations, 18 patients had moderate kidney insufficiency, and 10 had severe kidney insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In contrast, the risk of severe kidney impairment is low in patients with unilateral Wilms tumor treated without nephrotoxic chemotherapy or ionizing radiation [
         <a href="#rid108">
          108,109
         </a>
         ]. In a long-term (median 19.6 years) follow-up study of 75 survivors of nonsyndromic unilateral Wilms tumor who underwent unilateral nephrectomy without receiving nephrotoxic chemotherapy or ionizing radiation, 21 percent had mild kidney dysfunction (ie, stage II chronic kidney disease [CKD]  (
         <a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">
          table 5
         </a>
         )); no patients had stage III or more severe CKD [
         <a href="#rid109">
          109
         </a>
         ]. In another study of 37 survivors of childhood Wilms tumor (95 percent had unilateral disease; 60 percent had received radiation therapy) who were followed for a median of 22.5 years, 53 percent developed stage II CKD, one patient developed stage III CKD, and no patients had end-stage kidney disease (ESKD) [
         <a href="#rid110">
          110
         </a>
         ]. Hypertension was noted in 40 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ESKD requiring kidney replacement therapy is rare following treatment for Wilms tumor, and, when it occurs, it is usually associated with bilateral tumor involvement. Other causes of ESKD include Denys-Drash syndrome, radiation nephritis, or WAGR syndrome (
         <strong>
          W
         </strong>
         ilms tumor,
         <strong>
          a
         </strong>
         niridia,
         <strong>
          g
         </strong>
         enitourinary anomalies, and intellectual disability [mental
         <strong>
          r
         </strong>
         etardation]) [
         <a href="#rid111">
          111-113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'WAGR syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Denys-Drash syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiotoxicity
         </strong>
         – Treatment with anthracyclines (eg,
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         ) may cause cardiovascular complications including heart failure and increased left ventricular afterload [
         <a href="#rid114">
          114,115
         </a>
         ]. Risk of developing cardiac abnormalities is dependent upon the cumulative dose and dose intensity used. In a report of 97 patients with Wilms tumor who received doxorubicin (mean cumulative dose 303 mg/m
         <sup>
          2
         </sup>
         ), 25 percent of patients had evidence of increased left ventricular afterload documented by echocardiography [
         <a href="#rid115">
          115
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatotoxicity
         </strong>
         – Chemotherapy (
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         ) and hepatic radiation therapy can cause severe hepatopathy [
         <a href="#rid116">
          116-118
         </a>
         ]. This includes sinusoidal obstruction syndrome (SOS), which has been observed in patients receiving treatment for pediatric tumors that does not include hematopoietic cell transplantation [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129810.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incidence of hepatopathy and/or SOS is variable in patients with Wilms tumor, with estimates ranging from 1 to 14 percent [
         <a href="#rid116">
          116-118
         </a>
         ]. Some studies suggest that the incidence may be related to chemotherapy dosing [
         <a href="#rid117">
          117
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most patients with mild or moderate treatment-related hepatopathy can subsequently receive chemotherapy, following treatment protocol guidelines. Limited data also suggest that most patients with Wilms tumor who develop severe hepatopathy may also be able to safely continue or restart chemotherapy. In one observational study of 8862 patients treated for Wilms tumor on the National Wilms Tumor Study protocols 3 to 5, 71 patients (0.8 percent) were diagnosed with severe hepatopathy; this excluded those with WHO grade 1 or II transaminase elevations without signs or symptoms of sinusoidal obstructive syndrome [
         <a href="#rid118">
          118
         </a>
         ]. Severe hepatopathy most commonly occurred after actinomycin D and
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         courses (80 percent) with a median onset of 51 days. Among this cohort with severe hepatopathy, most patients (85 percent) were able to either continue (14 patients) or restart chemotherapy after a treatment delay (45 patients). For those patients who restarted chemotherapy after a delay, 14 did so at full dose and 12 were alive and disease-free at five years. Among the 10 patients who were unable to restart chemotherapy, four patients died from severe hepatopathy and six patients were alive and disease-free at follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fertility
         </strong>
         – Patients with Wilms tumor generally do not have infertility problems. However, females who received high doses of abdominal radiation have higher risk of infertility, pregnancy complications, perinatal mortality, and low birth weight babies [
         <a href="#rid119">
          119-121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second malignancies
         </strong>
         – Patients with Wilms tumors are at increased risk for developing second malignancies. In a report from the NWTS group that reviewed the late outcome of 5278 patients treated between 1969 and 1991, there were 43 cases of second neoplasms [
         <a href="#rid122">
          122
         </a>
         ]. The overall risk was estimated to be 1.6 percent at 15 years, and the highest risk was among patients who received radiation therapy and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         . All reported second solid tumors occurred within the radiation field and were detected at a mean of 16.1 years post-therapy for the original Wilms tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a report from the Childhood Cancer Survivor Study, 3 percent of survivors developed second malignancies 25 years after initial diagnosis of Wilms tumor [
         <a href="#rid101">
          101
         </a>
         ]. In another study of a large international cohort of patients diagnosed with Wilms tumor before 15 years of age during 1960 to 2004, 174 solid tumors and 28 leukemias were detected in 13,357 patients after observation through 2005 [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the previously described British Childhood Cancer Study, secondary malignancies accounted for three-quarters of excess late deaths among five-year survivors of Wilms tumor [
         <a href="#rid89">
          89
         </a>
         ]. Bowel and breast cancers were most frequent, and radiation therapy was an important predictor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other adverse effects from radiation
         </strong>
         – Other complications resulting from radiation therapy include muscle atrophy, short stature, and scoliosis. Children who receive 10 radiation absorbed dose (Gy) or more at an age younger than one year are most likely to have growth (height) impairment. Stature loss is due to the extension of standard flank radiation over the spinal column [
         <a href="#rid124">
          124,125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Radiation to the chest for lung metastases may result in thyroid disease and damage mammary tissue in young patients. Higher doses of radiation to the liver are associated with increased risk of portal hypertension [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with Wilms tumor should be examined on a regular basis by a clinician who is familiar with the natural history of the disease and the complications of therapy. Follow-up care includes ongoing surveillance for tumor recurrence and late treatment-related complications.
        </p>
        <p>
         The primary care provider can often provide routine care with coordinated scheduled visits to the oncologist, especially if the patient's family lives some distance from the oncology treatment center. Long-term follow-up guidelines for children who have received treatment for cancer in childhood are available at the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=6237" target="_blank">
          Children's Oncology Group (COG) website
         </a>
         .
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Screening for tumor recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing surveillance usually alternates chest radiography and abdominal ultrasound with chest, abdomen, and pelvic computed tomography (CT). Imaging studies are performed every six to eight weeks during therapy, then every three months for two years, followed by every six months for an additional two years. We perform more frequent abdominal ultrasounds in selected patients, as discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary surveillance
         </strong>
         – The lung is the most frequent first site of recurrence. Although tumor recurrence is best detected by lung CT, this modality is associated with increased radiation exposure compared with chest radiography. As a result, there is no consensus regarding the best modality for screening or the frequency of screening. As noted above, we alternate modalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal surveillance
         </strong>
         – Abdominal ultrasonography is performed to detect tumor recurrence in residual kidney tissue or another abdominal location. Abdominal ultrasound can detect early infradiaphragmatic relapses, which may be seen in patients with stage II and III tumor. The frequency of ultrasonography is dependent on whether nephrogenic rests (foci of persistent metanephric cells) were identified in the kidney(s) at the time of initial tumor diagnosis. Patients with nephrogenic rests are at increased risk for relapse. (See
         <a class="local">
          'Tumor recurrence'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At our institution, we utilize the following schedule for abdominal ultrasonography [
         <a href="#rid127">
          127
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with nephrogenic rests or those with tumor-predisposing syndromes (WAGR, Denys-Drash, or Beckwith-Wiedemann syndromes), examinations are performed every three months until the child is eight years old.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients without nephrogenic rests or tumor-predisposing syndromes, examinations are performed every three months for two years and then every six months for an additional two years.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Screening for therapy-related complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Screening for late complications is based upon the expected likelihood of adverse events related to the therapeutic regimens used. Many of these complications, as previously described, can be detected by history, physical examination, assessment of serum creatinine and urinalysis, and echocardiogram. (See
         <a class="local">
          'Late effects'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles of management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with suspected Wilms tumor should be referred to a pediatric cancer center for evaluation and treatment. Most children with newly diagnosed Wilms tumor are treated on research protocols, and treatment generally involves multimodal therapy (surgery, chemotherapy, and radiation). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The two major research groups that care for the largest number of patients with Wilms tumor are the Children's Oncology Group (COG) and the International Society of Paediatric Oncology (SIOP). Both COG and SIOP use risk-directed therapeutic regimens that are assigned based upon results of the initial staging, histologic classification, and molecular studies  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'COG approach'
         </a>
         above and
         <a class="local">
          'SIOP approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognostic factors
         </strong>
         – Several prognostic factors at the time of initial diagnosis are associated with an increased risk of tumor recurrence or death. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumor histology (see
         <a class="local">
          'Tumor histology'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumor stage  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Tumor stage'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Staging'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Molecular and genetic markers (see
         <a class="local">
          'Molecular markers'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;2 years (see
         <a class="local">
          'Age'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment modalities
         </strong>
         – Multimodal therapy for patients with unilateral Wilms tumor (stages I through IV) includes  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgical excision for all patients with resectable tumors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemotherapy for all patients, except those with very low-risk tumors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radiation therapy as indicated by stage and/or histology  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral Wilms tumor
         </strong>
         – Because the authors' institution is a member of the COG group, they treat patients with unilateral Wilms tumor with initial surgical resection, followed by chemotherapy  (
         <a class="graphic graphic_table graphicRef64794" href="/z/d/graphic/64794.html" rel="external">
          table 3
         </a>
         ). An alternate approach (used by the SIOP group) is to treat patients preoperatively with chemotherapy prior to surgical resection  (
         <a class="graphic graphic_table graphicRef106102" href="/z/d/graphic/106102.html" rel="external">
          table 4
         </a>
         ). Patients treated by either approach have excellent and comparable clinical outcomes. (See
         <a class="local">
          'Difference in approaches of COG and SIOP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral Wilms tumor
         </strong>
         – For patients with bilateral Wilms tumor (stage V)  (
         <a class="graphic graphic_table graphicRef78599" href="/z/d/graphic/78599.html" rel="external">
          table 2
         </a>
         ), we suggest preoperative chemotherapy with
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13202" href="/z/d/drug information/13202.html" rel="external">
          dactinomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         rather than other regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Following preoperative therapy, we suggest kidney parenchymal-sparing resection rather than more extensive bilateral kidney surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Postoperative chemotherapy with or without radiation is selected based on treatment response to neoadjuvant chemotherapy, histopathology, and tumor stage. This approach reduces the risk of end-stage kidney failure by facilitating early nephron-sparing surgery and preserving kidney parenchyma. (See
         <a class="local">
          'Bilateral kidney involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anaplastic histology
         </strong>
         – Patients with anaplastic histology  (
         <a class="graphic graphic_table graphicRef106103" href="/z/d/graphic/106103.html" rel="external">
          table 1
         </a>
         ) have a poor outcome. Intensive treatment regimens and new agents are under investigation in this population. (See
         <a class="local">
          'Anaplastic histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung metastases
         </strong>
         – For patients with lung metastases, treatment is tailored based upon the completeness of lung metastasis response after initial chemotherapy. For patients with complete resolution of pulmonary nodules after initial chemotherapy, lung irradiation is generally not needed. (See
         <a class="local">
          'Lung metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Overall five-year survival for Wilms tumor is 90 percent. Event-free survival (EFS) rates vary among individuals and are primarily dependent upon tumor histology and stage. (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent disease
         </strong>
         – The risk of tumor recurrence is dependent on tumor histology. Recurrent disease develops in 15 percent of children with favorable histology and in 50 percent of those with anaplastic features. Post-relapse four-year survival rates are 50 to 80 percent. (See
         <a class="local">
          'Tumor recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Long-term complications are related to the type and intensity of the treatment regimen. Patients with diffuse anaplastic tumors or higher-stage tumors receive more aggressive chemotherapy and radiation therapy and are at greater risk for both early and late adverse effects. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Long-term follow-up is necessary for survivors of Wilms tumor for ongoing surveillance for tumor recurrence and late treatment-related complications. This includes scheduled imaging of the chest (chest computed tomography [CT] or chest radiography) and abdomen (abdominal ultrasonography or CT). (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2998219028">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Jodi A Muscal, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf (Accessed on December 06, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol 2015; 33:2999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center. Hum Pathol 1988; 19:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981; 47:2302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ooms AH, Gadd S, Gerhard DS, et al. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 2016; 22:5582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow N, Churchill G, Beckwith JB, et al. Prognosis for Wilms' tumor patients with nonmetastatic disease at diagnosis--results of the second National Wilms' Tumor Study. J Clin Oncol 1985; 3:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996; 20:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonadio JF, Storer B, Norkool P, et al. Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol 1985; 3:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol 2006; 24:2352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Heuvel-Eibrink MM, van Tinteren H, Bergeron C, et al. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). Eur J Cancer 2015; 51:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weirich A, Leuschner I, Harms D, et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 2001; 12:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoba T, Urushihara N, Fukumoto K, et al. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors. J Pediatr Surg 2012; 47:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vujanić GM, Sandstedt B, Harms D, et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002; 38:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Breslow NE, Beckwith JB, et al. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study. J Clin Oncol 1993; 11:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998; 16:3744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blute ML, Kelalis PP, Offord KP, et al. Bilateral Wilms tumor. J Urol 1987; 138:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery BT, Kelalis PP, Blute ML, et al. Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study. J Urol 1991; 146:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994; 54:2331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study. J Clin Oncol 2011; 29:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23:7312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angio GJ. Pre- or postoperative therapy for Wilms' tumor? J Clin Oncol 2008; 26:4055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messahel B, Williams R, Ridolfi A, et al. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 2009; 45:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spreafico F, Gamba B, Mariani L, et al. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol 2013; 189:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segers H, van den Heuvel-Eibrink MM, Williams RD, et al. Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes Chromosomes Cancer 2013; 52:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chagtai T, Zill C, Dainese L, et al. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol 2016; 34:3195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratias EJ, Dome JS, Jennings LJ, et al. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol 2016; 34:3189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madanat-Harjuoja LM, Renfro LA, Klega K, et al. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. J Clin Oncol 2022; 40:3047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children’s Oncology Group studies AREN0532 and AREN0533. J Clin Oncol 2015; 33:10009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dome JS, Perlman EJ, Graf N. Risk stratification for wilms tumor: current approach and future directions. Am Soc Clin Oncol Educ Book 2014; :215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sredni ST, Gadd S, Huang CC, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 2009; 15:6800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams RD, Al-Saadi R, Chagtai T, et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 2010; 16:2036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang CC, Gadd S, Breslow N, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 2009; 15:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadd S, Huff V, Huang CC, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia 2012; 14:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow NE, Palmer NF, Hill LR, et al. Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study. Cancer 1978; 41:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow N, Sharples K, Beckwith JB, et al. Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1991; 68:2345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrigo S, Beckwith JB, Sharples K, et al. Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 1990; 66:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhard H, Aliani S, Ruebe C, et al. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol 2004; 22:4500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournade MF, Com-Nougué C, Voûte PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol 1993; 11:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournade MF, Com-Nougué C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 2001; 19:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs J, Kienecker K, Furtwängler R, et al. Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology. Ann Surg 2009; 249:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angio GJ. Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which. Med Pediatr Oncol 2003; 41:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet 2015; 386:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell C, Pritchard-Jones K, Shannon R, et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 2006; 42:2554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powis M, Messahel B, Hobson R, et al. Surgical complications after immediate nephrectomy versus preoperative chemotherapy in non-metastatic Wilms' tumour: findings from the 1991-2001 United Kingdom Children's Cancer Study Group UKW3 Trial. J Pediatr Surg 2013; 48:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA 1966; 198:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms' tumor: Results of the national Wilms' tumor study. Cancer 1976; 38:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989; 64:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998; 16:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999; 229:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frazier AL, Shamberger RC, Henderson TO, Diller L. Decision analysis to compare treatment strategies for Stage I/favorable histology Wilms tumor. Pediatr Blood Cancer 2010; 54:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010; 251:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez CV, Perlman EJ, Mullen EA, et al. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg 2017; 265:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001; 19:3719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez CV, Mullen EA, Chi YY, et al. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 2018; 36:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dix DB, Fernandez CV, Chi YY, et al. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol 2019; 37:2769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dix DB, Seibel NL, Chi YY, et al. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 2018; 36:1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bürger D, Moorman-Voestermans CG, Mildenberger H, et al. The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP). Z Kinderchir 1985; 40:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemerle J, Voute PA, Tournade MF, et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.). Cancer 1976; 38:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983; 1:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall G, Grant R, Weitzman S, et al. Predictors of surgical outcome in Wilms' tumor: a single-institution comparative experience. J Pediatr Surg 2006; 41:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Ann Surg 2011; 253:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrlich P, Chi YY, Chintagumpala MM, et al. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg 2017; 266:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chintagumpala MM, Perlman EJ, Tornwall B, et al. Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer 2022; 128:2493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchey ML, Coppes MJ. The management of synchronous bilateral Wilms tumor. Hematol Oncol Clin North Am 1995; 9:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz JR, Ritchey ML, Moksness J, et al. Renal salvage procedures in patients with synchronous bilateral Wilms' tumors: a report from the National Wilms' Tumor Study Group. J Pediatr Surg 1996; 31:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indolfi P, Jenkner A, Terenziani M, et al. Synchronous bilateral Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 2013; 119:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daw NC, Anderson JR, Hoffer FA, et al. A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study. J Clin Oncol 2014; 32:10032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller JI. Current standards of care and future directions for "high-risk" pediatric renal tumors: Anaplastic Wilms tumor and Rhabdoid tumor. Urol Oncol 2016; 34:50.
          </a>
         </li>
         <li class="breakAll">
          A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT. Study details available at: https://clinicaltrials.gov/ct2/show/NCT04322318 (Accessed on March 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verschuur A, Van Tinteren H, Graf N, et al. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol 2012; 30:3533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol 2002; 13:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Camargo B, Melaragno R, Saba e Silva N, et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 1994; 22:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994; 73:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995; 17:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loss JF, Santos PP, Leone LD, Brunetto AL. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 2004; 42:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 1993; 11:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994; 12:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinkerton CR, Pritchard J. A phase II study of ifosfamide in paediatric solid tumours. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987; 71:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt CB, Douglass EC, Etcubanas E, et al. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol 1989; 16:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saylors RL 3rd, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartzman E, Scopinaro M, Angueyra N. Phase II study of ifosfamide as a single drug for relapsed paediatric patients. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournade MF. A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. Eur J Cancer 2013; 49:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koshinaga T, Takimoto T, Oue T, et al. Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG). Pediatr Blood Cancer 2018; 65:e27056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotton CA, Peterson S, Norkool PA, et al. Early and late mortality after diagnosis of wilms tumor. J Clin Oncol 2009; 27:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong KF, Reulen RC, Winter DL, et al. Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study. J Clin Oncol 2016; 34:1772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irtan S, Jitlal M, Bate J, et al. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience. Eur J Cancer 2015; 51:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard-Jones K, Moroz V, Vujanic G, et al. Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol 2012; 23:2457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrlich PF, Anderson JR, Ritchey ML, et al. Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor. J Clin Oncol 2013; 31:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatramani R, Chi YY, Coppes MJ, et al. Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer 1999; 85:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007; 48:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008; 50:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002; 24:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989; 7:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dome JS, Bockhold CA, Li SM, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005; 23:9138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchey ML, Shamberger RC, Haase G, et al. Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group. J Am Coll Surg 2001; 192:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011; 57:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk IW, Oldenburger F, Cardous-Ubbink MC, et al. Evaluation of late adverse events in long-term wilms' tumor survivors. Int J Radiat Oncol Biol Phys 2010; 78:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster KL, Salehabadi SM, Green DM, et al. Clinical Assessment of Late Health Outcomes in Survivors of Wilms Tumor. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weil BR, Murphy AJ, Liu Q, et al. Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2023; 41:2638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange J, Peterson SM, Takashima JR, et al. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J Urol 2011; 186:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith GR, Thomas PR, Ritchey M, Norkool P. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. Am J Clin Oncol 1998; 21:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Interiano RB, McCarville MB, Santos ND, et al. Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor. J Pediatr Surg 2017; 52:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romao RL, Lorenzo AJ. Renal function in patients with Wilms tumor. Urol Oncol 2016; 34:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Interiano RB, Delos Santos N, Huang S, et al. Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer 2015; 121:2449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neu MA, Russo A, Wingerter A, et al. Prospective analysis of long-term renal function in survivors of childhood Wilms tumor. Pediatr Nephrol 2017; 32:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol 2003; 21:4579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005; 174:1972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigoriev Y, Lange J, Peterson SM, et al. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol 2012; 27:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19:1926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995; 13:1546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefft M, Mitus A, Das L, et al. Irradiation of the liver in children: review of experience in the acute and chronic phases, and in the intact normal and partially resected. Am J Roentgenol Radium Ther Nucl Med 1970; 108:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Norkool P, Breslow NE, et al. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 1990; 8:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oosterom N, Gooskens SLM, Renfro LA, et al. Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. J Clin Oncol 2023; 41:4247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green DM, Peabody EM, Nan B, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2002; 20:2506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalapurakal JA, Peterson S, Peabody EM, et al. Pregnancy outcomes after abdominal irradiation that included or excluded the pelvis in childhood Wilms tumor survivors: a report from the National Wilms Tumor Study. Int J Radiat Oncol Biol Phys 2004; 58:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne J, Mulvihill JJ, Connelly RR, et al. Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives. Med Pediatr Oncol 1988; 16:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995; 13:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer 2010; 127:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 2000; 46:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogeboom CJ, Grosser SC, Guthrie KA, et al. Stature loss following treatment for Wilms tumor. Med Pediatr Oncol 2001; 36:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warwick AB, Kalapurakal JA, Ou SS, et al. Portal hypertension in children with Wilms' tumor: a report from the National Wilms' Tumor Study Group. Int J Radiat Oncol Biol Phys 2010; 77:210.
          </a>
         </li>
         <li class="breakAll">
          Fernandez C, Geller JI, Ehrlich PF, et al. Renal tumors. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo P, Poplack D (Eds), Lippincott Williams &amp; Wilkins, St. Louis 2011. p.861.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6237 Version 52.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf (Accessed on December 06, 2015).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26304882" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2844645" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6164480" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27702824" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2984345" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prognosis for Wilms' tumor patients with nonmetastatic disease at diagnosis--results of the second National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712292" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2984344" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Anaplastic Wilms' tumor: clinical and pathologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710034" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592561" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11332141" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23217878" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11813170" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314292" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Current therapy for Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8380295" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9850017" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2821293" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bilateral Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1650403" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8162576" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189373" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16129848" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757319" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pre- or postoperative therapy for Wilms' tumor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19231157" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23174227" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24038759" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Gain of 1q is a marker of poor prognosis in Wilms' tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27432915" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400937" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35580298" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children’s Oncology Group studies AREN0532 and AREN0533.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24857079" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Risk stratification for wilms tumor: current approach and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19903788" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20332316" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208794" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22952427" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/205340" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1657352" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2167146" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15542800" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388918" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11208843" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19300220" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14595712" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26164096" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16904312" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24210183" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Surgical complications after immediate nephrectomy versus preoperative chemotherapy in non-metastatic Wilms' tumour: findings from the 1991-2001 United Kingdom Children's Cancer Study Group UKW3 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4288581" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chemotherapy in the treatment of leukemia and Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/184912" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The treatment of Wilms' tumor: Results of the national Wilms' tumor study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2544249" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440748" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10024113" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20052778" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Decision analysis to compare treatment strategies for Stage I/favorable histology Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142733" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27811504" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533093" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29211618" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31449468" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29659330" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2994320" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/184913" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6321673" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16677894" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Predictors of surgical outcome in Wilms' tumor: a single-institution comparative experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21394016" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28795993" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35383900" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8531856" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8591967" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The management of synchronous bilateral Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8863224" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Renal salvage procedures in patients with synchronous bilateral Wilms' tumors: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23310931" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Synchronous bilateral Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26612481" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Current standards of care and future directions for "high-risk" pediatric renal tumors: Anaplastic Wilms tumor and Rhabdoid tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26612481" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Current standards of care and future directions for "high-risk" pediatric renal tumors: Anaplastic Wilms tumor and Rhabdoid tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22927531" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11996479" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8107657" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313334" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7620926" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14752877" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8393095" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8164044" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2758566" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A phase II study of ifosfamide in paediatric solid tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3100034" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Phase II trial of ifosfamide in children with malignant solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2495567" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508177" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2503255" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2547529" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959164" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29630767" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19139431" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Early and late mortality after diagnosis of wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27022116" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25465191" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22415585" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23382471" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28097788" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10193955" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16547940" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17539021" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11990305" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2540289" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16172460" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11192924" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21384541" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20137867" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Evaluation of late adverse events in long-term wilms' tumor survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36300342" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical Assessment of Late Health Outcomes in Survivors of Wilms Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36693221" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21683387" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9499259" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27856008" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26278364" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Renal function in patients with Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25832759" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28451896" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Prospective analysis of long-term renal function in survivors of childhood Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14673045" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16217371" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22430485" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Treatments and outcomes for end-stage renal disease following Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283124" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7602343" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Cardiac function in Wilms' tumor survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4312896" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Irradiation of the liver in children: review of experience in the acute and chronic phases, and in the intact normal and partially resected.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2167951" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37343199" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12011129" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15050311" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Pregnancy outcomes after abdominal irradiation that included or excluded the pelvis in childhood Wilms tumor survivors: a report from the National Wilms Tumor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2843733" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7636528" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19950224" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Secondary malignant neoplasms after Wilms tumor: an international collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10725637" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Late effects in children treated with radiation therapy for Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11452938" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Stature loss following treatment for Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19695791" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Portal hypertension in children with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
